Retraining and Control Therapy (ReACT)- Adults
NCT06570954, Not applicable, Recruiting, University of Alabama at Birmingham
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Retraining and Control Therapy (ReACT)- Adults | ClinicalTrials.gov |
| NCT number | NCT06570954 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Alabama at Birmingham | ClinicalTrials.gov |
| Conditions | Convulsion, Non-Epileptic | ClinicalTrials.gov |
| Interventions | ReACT | ClinicalTrials.gov |
| First posted | 2024-08-26 | ClinicalTrials.gov |
| Last updated | 2026-06-11 | ClinicalTrials.gov |
Registered outcomes 43
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Magic and turbulence task | 6-12 months | Measure of perceived sense of control in response to tasks in which control is manipulated; Greater negative numbers indicate improved understanding of control. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions. | ClinicalTrials.gov |
| Primary | Pain catastrophizing scale- situation specific | 6-12 months | Measures catastrophic symptom expectations; score ranges from 0-52, higher scores indicate greater levels of pain-related anxiety. Assessment done after performing Cold Pressor Test. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions. | ClinicalTrials.gov |
| Primary | Pain tolerance (time) | 6-12 months | Measures catastrophic symptom expectations. Measured by the total time the participant can keep their hand in cool water during the Cold Pressor Test. Shorter time indicates less pain tolerance. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions. | ClinicalTrials.gov |
| Primary | Salivary Cortisol | 6-12 months | Measures catastrophic symptom expectations. Measured before and after the cold pressor test. Increased cortisol response indicate increased perceived pain severity. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions. | ClinicalTrials.gov |
| Primary | Pain Rating Scale | 6-12 months | Measures perceived pain severity after the CPT; score ranges from 0-100. Higher scores indicate greater perceived pain severity. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions. | ClinicalTrials.gov |
| Primary | Stroop task | 6-12 months | Measure of cognitive inhibition and selective attention, higher scores means poorer cognitive inhibition and selective attention. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | PNES Frequency | 16-22 months | Measured by Psychogenic Non-epileptic Seizures (PNES) diary, including frequency, premonitory symptoms, description of PNES symptoms and duration. Assessed 30 days before baseline visit to 12 months after the 12th treatment session. | ClinicalTrials.gov |
| Secondary | Pain Catastrophizing Scale (PCS)- General | 6-12 months | Measures catastrophic symptom expectations; score ranges from 0-52, higher scores indicate greater levels of pain-related anxiety. Assessment done before performing Cold Pressor Test. Assessed at baseline visit, and 1 week and 2 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | Anxiety Sensitivity Index (ASI) | 16-22 months | Assesses catastrophic symptom expectations; scores ranges from 0-64, higher scores indicate greater anxiety. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | Shipley | At Baseline | Assesses verbal IQ; higher scores indicate greater verbal IQ. Completed by participant. Assessed at baseline visit. | ClinicalTrials.gov |
| Secondary | Quality of Life in Epilepsy (QOLIE-31) | 16-22 months | Assesses health-related quality of life for patients with epilepsy (used in PNES participants by instructing them to consider their PNES when asked about "seizures"); score ranges from 0-100, higher scores indicate better functioning and well-being. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions | ClinicalTrials.gov |
| Secondary | Sense of Agency Question | 16-22 months | Single question which asks "How much control do you believe you have over your PNES?", scored using a 4-point Likert scale. Lower score indicates better control over PNES. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | LEVEL 2-Somatic Symptom report adapted from the Participant Health Questionnaire | 16-22 months | Measures symptom severity; scores ranges from 0-26, higher scores indicate greater symptom severity. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | WHO Disability Assessment Schedule (WHODAS2.0) | 16-22 months | Completed by participant to measure physical functioning and disability in patients with chronic pain; score ranges from 0-100, higher scores indicate greater perceived functional disability. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions | ClinicalTrials.gov |
| Secondary | The Impact on Family Scale | 16-22 months | Assesses participant's perceptions of the impact of their medical condition on the family; higher scores indicate greater financial burden on the family. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | Childhood Trauma Questionnaire | At baseline | History of physical, sexual and/or emotional abuse and physical and emotional neglect. All clinical subscales have a score range of 5-25, higher scores indicate greater abuse/neglect. Completed by participant. Assessed at baseline visit. | ClinicalTrials.gov |
| Secondary | Hospital Anxiety and Depression Scale (HADS) | 16-22 months | Measures anxiety and depression symptoms in patients; scores ranges from 0-21 for subscales, higher scores indicate increased symptom severity. Completed by participant. Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | The Columbia Suicide Severity Rating Scale (C-SSRS) | 16-22 months | Measure that addresses the full range of suicidal thoughts and behaviors that suggest a person is at heightened risk of committing suicide; score ranges from 0-25, higher score indicates greater suicidal ideation intensity. Completed by trained research study coordinator.Assessed at baseline visit, and 1 week, 2 months, 6 months and 12 months after the final therapy sessions. | ClinicalTrials.gov |
| Secondary | Healthcare Related Stigma Questionnaire | At baseline | Measures stigma in patients related to their interaction with health care; scores ranges from 0-64, higher scores indicate greater stigma. Completed by participant. Assessed at baseline visit. | ClinicalTrials.gov |
| Secondary | Flanker Inhibitory Control and Attention Subtest | 6-12 months | Subtest of the National Institute of Health Toolbox Cognition Battery. Measures executive function and attention; higher scores indicate better performance. Completed by participant. Assessed at 1st therapy session, and 1 week and 2 months after 12th therapy session. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R61MH127155 | Retraining and Control Therapy (ReACT): Sense of control and catastrophic symptom expectations as targets of a cognitive behavioral treatment for pediatric psychogenic non-epileptic seizures (PNES) | FOBIAN, AARON D | UNIVERSITY OF ALABAMA AT BIRMINGHAM | NATIONAL INSTITUTE OF MENTAL HEALTH | 2021 to 2022 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Dimensional Change Card Sort | Secondary outcome | ConductCognition |
| Pattern and Letter Comparison | Secondary outcome | ConductCognition |
| Picture Order Memory Test | Secondary outcome | ConductCognition |
| Size Order Memory Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)